Summary & Overview
HCPCS J2920: Methylprednisolone Sodium Succinate Injection, up to 40 mg
HCPCS Level II code J2920 describes the parenteral supply of methylprednisolone sodium succinate, up to 40 mg. This injectable corticosteroid is commonly used for anti-inflammatory and immunosuppressive indications across outpatient and procedural settings. Nationally, utilization of steroid injectables influences drug-cost management, site-of-service billing practices, and formulary policies for both commercial insurers and Medicare.
Key payers in the scope of analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J2920, standard sites of service where the product is administered, and commonly tracked billing considerations. The publication outlines reimbursement benchmarking approaches, relevant policy updates affecting HCPCS drug coding and payment, and operational implications for billing and revenue-cycle teams.
Where input data is incomplete, the publication notes missing elements rather than inferring values. The goal is to equip payers, billing professionals, and clinical administrators with a clear reference for the code's clinical meaning, expected service settings, and the national payer landscape relevant to injectable corticosteroid billing.
Billing Code Overview
HCPCS Level II code J2920 represents an injection of methylprednisolone sodium succinate, up to 40 mg. This is a corticosteroid medication supplied for parenteral administration.
Service type: Drug administration (intramuscular or intra-articular/subcutaneous/parenteral injectable steroid)
Typical site of service: Outpatient clinics, physician offices, ambulatory surgical centers, and hospital outpatient departments
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of chronic lumbar radiculopathy and episodic inflammatory flares presents to an outpatient ambulatory infusion suite for an intramuscular or intra-articular corticosteroid injection. The clinician documents focal pain, reduced range of motion, and a trial of conservative therapies (NSAIDs, physical therapy) with inadequate relief. After informed consent, the provider prepares methylprednisolone sodium succinate up to 40 mg for administration. Typical workflow: pre-procedure assessment (vitals, allergy review, anticoagulation status), site preparation and optional local anesthetic, administration of the injection (intramuscular, intra-articular, or periarticular), post-procedure monitoring for immediate adverse reaction, and brief discharge instructions. The service commonly occurs in an outpatient clinic, physician office, ambulatory surgery center, or outpatient infusion center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Service performed by the billing provider | Use when the submitting physician performed the injection personally. |
22 | Increased procedural services |